I-CAR T cell therapy, i-groundbreaking immunotherapy, ithuthuka endaweni yezokwelapha yase-Malaysia. Lokhu kwelashwa okusha kuhilela ukuguqula izakhi zofuzo amaseli T esiguli ukuze abone futhi ahlasele amangqamuzana omdlavuza. Nakuba ekuqaleni itholakala emazweni athuthukile, umkhakha wezokunakekelwa kwempilo waseMalaysia uyayamukela le ndlela ephambili. Izibhedlela eziningana nezikhungo zocwaningo zihlola amandla e-CAR T cell therapy, okunikeza ithemba ezigulini ezinezinhlobo ezithile zomdlavuza wegazi, njenge-leukemia ne-lymphoma. Izinselelo zisaqhubeka, okuhlanganisa izindleko nengqalasizinda, kodwa ukusebenzisana phakathi kwezikhungo nezimboni kuhloswe ukunweba ukufinyelela. Njengoba iMalaysia ithuthuka ku-biotechnology nokunakekelwa kwezempilo, ukwelashwa kwamaseli e-CAR T kuthembisa umthelela oguqulayo ekunakekelweni komdlavuza.
I-MALAYSIAN Genomics Resource Center Bhd (MGRC) uthemba ukwenza i-chimeric antigen receptor yayo (CAR) Ukwelashwa kwe-T-Cell Ukwelashwa okutholakala e-Malaysia ngaphansi kuka-RM200,000 okungukuthi cishe u-$45,000 USD, okuyingxenyana yezindleko zokwelapha e-Europe nase-United States. Ngethemba ukuthi ukwelashwa kwe-CAR T-Cell e-Malaysia kuzoletha injabulo ezinkulungwaneni zeziguli ezinethemba lokuthola lokhu kwelashwa okuphumelelayo.
Isithombe: I-CAR T Ukwelashwa kwamaseli kusungulwe ezinye izinhlobo zamathumba aqinile
Ngokusho kukaSasha Nordin oyisikhulu esiphezulu seMalaysian Genomics, le nkampani ibambisene nenkampani yaseChina i-ICARTAB Biomedical Co Ltd, ethuthukisa lobu buchwepheshe ukuze bathole izifo ezibulalayo eziqinile, naphezu kweqiniso lokuthi izindlela zokwelapha ezifanayo zezifo eziwuketshezi noma zegazi seziyatholakala emazweni aseNtshonalanga.
"Ukuthuthukisa ukufinyelela ezintweni ezintsha kuyingxenye yesibopho sethu." Sikwazile ukufinyelela esivumelwaneni esisivumela ukuthi siyenze itholakale ezigulini eziseNingizimu-mpumalanga ye-Asia ngengxenye yentengo.
Engxoxweni abe nayo ne-Malaysian Reserve izolo, uthe, “Sisebenzela ukuthi itholakale ngemali engaphansi kuka-R200,000 uma iqhathaniswa no-US$400,000 (RM1.61 million) okungenani e-Europe nase-US.”
I-MGRC izoba ngumsabalalisi osemthethweni wokwelashwa kwe-CAR T-Cell eSingapore, Brunei, Indonesia, Thailand, Vietnam, Cambodia, naseLaos, ngaphezu kweMalaysia.
Ngokuka-Sasha Omar, inkampani njengamanje inemithi yezifo eziyisithupha kweziyishumi eziphambili esifundeni, okuhlanganisa isibindi, i-pancreatic, i-mesothelioma, i-oesophagus, ubuchopho, nezimila zesisu. Uthi i-CAR T-cell immunotherapy yomdlavuza oqinile akuyona indlela yokwelapha ekhiqizwa ngobuningi.
Yonke imithi yokwelapha iyingqayizivele esigulini njengoba ihlanganisa ukukhipha amangqamuzana esiguli kanye nokuvumela i-T-cell yesiguli, ingqamuzana elimhlophe legazi elibalulekile esimisweni sokuzivikela ezifweni, ukuba libone isimila.
I-T-cell izobe isibuyiselwa emzimbeni wesiguli ukuze ibone futhi ilwe nengqamuzana eliyingozi, ivimbele ukuthi lingasakazeki ngokuqhubekayo.
“Ngaso sonke isikhathi uma sihlangana nesiguli, kufanele sidlule ohlelweni lweziqu ukuze sihlole ukuthi sikulungele yini ukuthola i-CAR T-Cell therapy.” Uma ehlangabezana nazo zonke izimfuneko, sizokhiqiza ama-T-cell aleso siguli kuphela.
"Kungakho sikholelwa ukuthi kubalulekile ukulenza lithengeke kakhulu." Singakwazi ukulawula amanani kangcono ngokufaka elebhu yethu,” kusho yena.
USasha Omar uthe ilabhorethri entsha yenkampani izosebenza ekupheleni kukaMashi kulo nyaka, nokuthi imisebenzi izophinda iqale ngokushesha ukuze kuhlangatshezwane nesidingo sokwelashwa.
Indawo entsha engu-12,000 sq ft izoba se-Kota Damansara, nelabhorethri ithatha indawo engaba ngu-7,000 sq ft kanye nesakhiwo sehhovisi sithatha indawo esele.
Izidakamizwa ezisanda kwakhiwa, njenge-CAR-T (chimeric antigen receptor T-cell), ziyimithi eshintsha impilo yabantu asebesebenzise izindlela zabo zokwelapha ezingase zibe khona. Lezi zindlela zokwelapha ezisezingeni eliphezulu zihlinzekwa ngezindlela okungezona ezendabuko, okuhlanganisa uchungechunge olude, oluyinkimbinkimbi, noluhlelwe kakhulu lwemisebenzi ngaphakathi kwezikhungo zomhlinzeki wezempilo. Abahlinzeki bazozuza kulokhu kwelashwa ngezindlela ezihlukahlukene, kusukela ekuthuthukiseni isithunzi sabo njengenhlangano esezingeni eliphezulu ukuya ekuhlinzekeni ngezinhlelo ezikhiqiza inzuzo ephezulu. Kodwa-ke, ukuletha lokhu kwelashwa kwakamuva okuthuthukile kubangela izinselele ezinkulu zezezimali nokusebenza uma kungahlolisiswa futhi kulungiselelwe ngokucophelela.
Ukwelashwa kwe-CAR T-Cell kuwuhlobo lwe-immunotherapy olusebenzisa ama-T-cell aguqulwe ngokukhethekile ayingxenye yohlelo lwethu lokuzivikela ezifweni silwe nomdlavuza. Isampula yeziguli T amaseli aqoqwa egazini, bese eguqulwa ukuze akhiqize izakhiwo ezikhethekile ezibizwa nge-chimeric antigen receptors (CAR) ebusweni bazo. Lapho la maseli e-CAR ashintshiwe ebuyiselwa esigulini, lawa maseli amasha ahlasela i-antigen ethile futhi abulale amaseli wesimila.
Ukwelashwa kwe-CAR T-cell kuthatha usizo kumasosha omzimba uqobo ukuze kuhlasele futhi kubulale amangqamuzana omdlavuza. Lokhu kwenziwa ngokususa amanye amaseli abekiwe egazini lesiguli, uwaguqule elebhu bese uwajova kabusha esigulini. Ukwelashwa kwe-CAR T-cell kukhiqize imiphumela ekhuthazayo kakhulu kwi-Non-Hodgkin lymphoma futhi ngenxa yalokho yamukelwa FDA.
Okwamanje FDA igunyaze ukwelashwa kwe-CAR T-Cell kwezinye izinhlobo zolaka neziphikisayo I-Non-Hodgkin lymphoma, i-Myeloma futhi ibuyele emuva futhi iphikisa i-leukemia enamandla ye-lymphoblastic. Isiguli sidinga ukuthumela imibiko yezokwelapha ephelele ukuze siqinisekise ukusetshenziswa kokwelashwa kwe-CAR T-Cell ekwelapheni kwaso.
1. Iziguli ezine-CD19 + B-cell Lymphoma (Okungenani ukuhlanganiswa kwangaphambili okungu-2 imiphumela emibi yokwelashwa ngamakhemikhali izinhlobo)
2.Ukuba neminyaka eyi-3 kuye kwengama-75
3. Isilinganiso se-ECOG ≤2
4. Abesifazane abanamandla okuthola izingane kumele babe nomchamo ukukhulelwa ukuhlolwa okwenziwe kwatholakala ukuthi une-negative ngaphambi kokwelashwa. Zonke iziguli ziyavuma ukusebenzisa izindlela ezithembekile zokuvimbela inzalo ngesikhathi sesilingo kuze kube kulandelwa okokugcina.
1.Ukuphakama komfutho wegazi ophakeme noma ukuquleka
2. Ukwehluleka kokuphefumula
3. Kusatshalaliswe i-coagulation ye-intravascular
4. I-Hematosepsis noma ukutheleleka okusebenzayo okungalawulwa
5. Okungalawulwa sikashukela
1. Ukuhlolwa nokuhlolwa: isonto elilodwa
2. Pre-treatment & T-Cell Collection: isonto elilodwa
3. Ukulungiswa kweT-Cell nokubuyiselwa: amasonto amabili-amathathu
4. 1st Ukusebenza ngempumelelo: amasonto amathathu
5. Ukuhlaziywa kokuphumelela kwesibili: amasonto amathathu
Izindleko zokwelashwa kwe-CAR T-Cell e-Malaysia zizoba cishe phakathi $ 45000 - 50,000 USD. Ukuze uthole imininingwane ngemibandela yokufaneleka kanye nesilinganiso sezindleko sicela uthumele imibiko yakho yezokwelapha ku info@cancerfax.com ngegama lakho neminyaka yakho njengesihloko.
Funda nalokhu: Ukwelashwa kwe-CAR T Cell eNdiya
Imiphumela emibi ejwayelekile yokwelashwa kwe-CAR T-cell ifaka:
Ukwelashwa kwe-CAR T-cell ekwelapheni i-lymphoma namanye amagciwane egazi kubonise imiphumela ethembisayo. Kusukela ekwelashweni kwe-CAR T-cell, iziguli eziningi ezazibuye zibuyele emuva izicubu zegazi zazinemiphumela ethembisayo futhi zingenabo ubufakazi bomdlavuza. Iphinde yasiza ekuvuseleleni iziguli esezihlulekile ngaphambilini ukuphendula kuningi lokwelashwa kwendabuko komdlavuza.
Kodwa-ke, izifundo zesikhathi eside zesibalo esikhulu sesiguli ziyadingeka ukuqinisekisa ukusebenza kwalokhu kwelashwa. Ukuhlolwa okukhulu kuzosiza ekutholeni amathuba okuba nemiphumela engemihle nezindlela ezifanele zokubhekana nayo.
Ngingakuthola kanjani ukwelashwa e-Malaysia?